【摘要】 目的:评价重组人血小板生成素(rh TPO)与重组人白细胞介素11(rh IL-11)治疗血小板减少症的疗效与安全性。方法:检索Cochrane图书馆、Pub Med、EMBASE、万方数据库、维普中文数据库、同方中文数据库,纳入重组人血小板生成素与重组人白细胞介素11治疗血小板减少症的所有随机对照试验,采用Rev Man 5.0软件对数据进行Meta分析。结果:共纳入10篇文献,合计532例患者。Meta分析结果显示,rh TPO在化疗后血小板恢复至≥1.0×1011·L-1所需时间(MD=-4.39,95%CI:-5.62~-3.16,P<0.01)、化疗前后血小板升高值(MD=51.36,95%CI:10.23~92.50,P=0.01)、血小板输注比例(OR=0.31,95%CI:0.14~0.67,P<0.01)等方面均优于rh IL-11,rh IL-11组不良反应发生率高于rh TPO组(OR=0.11,95%CI:0.06~0.23,P<0.01)。结论:rh TPO在相同时间提升血小板计数,恢复血小板至正常值方面均优于rh IL-11,且不良反应发生率及血小板输注比例更低。更多还原

【Abstract】 Objective: To compare the efficacy and safety of recombinant human thrombopoietin( rh TPO) with recombinant human interleukins 11( rh IL-11) in the treatment of thrombocytopenia. Methods: "Thrombopoietin and rh IL-11"were searched in database which includes Cochrane Library,Pub Med,Wanfang data resource,VIP database and CNKI; the censor date was from the time of building database to April 2014. All the calculation and statistical tests were done with Rev Man 5. 0 software. Results: Totally 10 trials with 532 subjects meeting the criteria were include in this review. All the studies were evaluated strictly according to Jadad standard,and Meta-analysis were adopted. A Meta-analysis showed that the time needed for platelet recovery after chemotherapy to 1. 0 × 1011·L- 1( MD =- 4. 39,95% CI:- 5. 62-- 3. 16,P <0. 01),higher platelet values before and after chemotherapy( MD = 51. 36,95% CI: 10. 23-92. 50,P = 0. 01),proportion of platelet infusion( OR = 0. 31,95% CI: 0. 14-0. 67,P < 0. 01) of rh TPO were better than that of rh IL-11,proportion of ADR of rh TPO was lower than rh IL-11( OR = 0. 11,95% CI: 0. 06-0. 23,P < 0. 01). Conclusion: rh TPO was better than rh IL-11 on the same time enhance the platelet count and restore normal,also,it had less adverse reaction and low incidence of platelet infusion rate.更多还原